Because the evidence for FCGR2A and sCD163 as potential biomarkers to distinguish different types of HLH was generated from studies that only included certain types of HLH, validation studies should include all types of HLH to produce definitive conclusions. The gene discussed is CD163; the disease is hemophagocytic syndrome.